drugset / Trial / NCT00882180
Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ALN-VSP02, an RNAi therapeutic, in patients with advanced solid tumors with liver involvement.
Timeline
- Start
- 2009-03
- Primary completion
- 2011-07
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALN-VSP02 | Small interfering RNA (siRNA) | — | Intravenous |